Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Inovio: Successful Phase 2 Trial in Cervical Dysplasia Provides Proof of Concept for the Technology Base (INO, $12.98, Neutral, Subscribers Only)

Inovioís Immunotherapy Technology Base

Over two decades ago, the creation of naked DNA vaccines gave the promise of a significant advance…
Read more…

This Could Be the Coming Out Year for Inovio (INO, $0.72)

I had the opportunity to meet with some of Inovio's (INO) management team- Joseph Kim (Chief Executive Officer), Peter Kies…
Read more…